Acrospire Investment Management LLC grew its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 633.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,200 shares of the biopharmaceutical company’s stock after buying an additional 1,900 shares during the quarter. Acrospire Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $123,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the period. Keel Point LLC boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 18 shares during the period. Shayne & CO. LLC boosted its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 24 shares during the period. Finally, Chilton Investment Co. LLC boosted its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the period. Institutional investors and hedge funds own 69.82% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.97 on Thursday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market capitalization of $101,508.14, a P/E ratio of 20.95, a price-to-earnings-growth ratio of 2.35 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter last year, the company earned $0.77 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.23% of the company’s stock.

A number of equities analysts recently commented on BMY shares. UBS reissued a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets reissued a “sell” rating and set a $49.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Finally, Citigroup increased their price target on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $64.93.

TRADEMARK VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/acrospire-investment-management-llc-has-123000-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.